ALLMedicine™ Acute Graft Versus Host Disease Center
Research & Reviews 262 results
https://clinicaltrials.gov/ct2/show/NCT04144036
Aug 3rd, 2022 - Eligible patients will receive Neihulizumab weekly, for up to four doses. Responding patients, and patients with stable disease should receive all four weekly doses. Patients with skin only disease that clinically progresses by one stage (e.g, fro...
https://clinicaltrials.gov/ct2/show/NCT03057054
Jul 21st, 2022 - PRIMARY OBJECTIVE: I. To determine efficacy of orally-administered Lactobacillus plantarum (LBP) in preventing the development of gastrointestinal (GI) acute graft versus host disease (aGvHD) in children and adolescents undergoing alternative dono...
https://doi.org/10.1016/j.leukres.2022.106918
Leukemia Research; Barkhordar M, Kasaeian A et. al.
Jul 18th, 2022 - In the evolution of haploidentical hematopoietic stem cell transplantation (haplo-HSCT), In vivo T-cell modulation with concomitant use of anti-thymocyte globulin (ATG) and high-dose post-transplant cyclophosphamide (PTCy) provides a novel promisi...
https://clinicaltrials.gov/ct2/show/NCT05457556
Jul 14th, 2022 - PRIMARY OBJECTIVES: I. To compare the 1-year cumulative incidence of severe GVHD (from day of HCT) defined as Grade III-IV acute GVHD (aGVHD) and/or chronic GVHD (cGVHD) that requires systemic immunosuppression and to compare the disease free surv...
https://clinicaltrials.gov/ct2/show/NCT04006652
Jul 13th, 2022 - Finding a donor remains a challenge for patients in need of an urgent hematopoietic stem cell transplantation (HSCT). The ability to obtain half matched stem cells from any family member represents a significant breakthrough in the field. Haploide...
Drugs 1 results see all →
Clinicaltrials.gov 133 results
https://clinicaltrials.gov/ct2/show/NCT04144036
Aug 3rd, 2022 - Eligible patients will receive Neihulizumab weekly, for up to four doses. Responding patients, and patients with stable disease should receive all four weekly doses. Patients with skin only disease that clinically progresses by one stage (e.g, fro...
https://clinicaltrials.gov/ct2/show/NCT03057054
Jul 21st, 2022 - PRIMARY OBJECTIVE: I. To determine efficacy of orally-administered Lactobacillus plantarum (LBP) in preventing the development of gastrointestinal (GI) acute graft versus host disease (aGvHD) in children and adolescents undergoing alternative dono...
https://clinicaltrials.gov/ct2/show/NCT05457556
Jul 14th, 2022 - PRIMARY OBJECTIVES: I. To compare the 1-year cumulative incidence of severe GVHD (from day of HCT) defined as Grade III-IV acute GVHD (aGVHD) and/or chronic GVHD (cGVHD) that requires systemic immunosuppression and to compare the disease free surv...
https://clinicaltrials.gov/ct2/show/NCT04006652
Jul 13th, 2022 - Finding a donor remains a challenge for patients in need of an urgent hematopoietic stem cell transplantation (HSCT). The ability to obtain half matched stem cells from any family member represents a significant breakthrough in the field. Haploide...
https://clinicaltrials.gov/ct2/show/NCT04744116
Jul 12th, 2022 - PRIMARY OBJECTIVE: I. To estimate between-arm differences (Arm 3 versus [vs] Arm 1, and Arm 2 vs Arm 1) for each of the 28-day co-primary outcome probabilities. OUTLINE: Patients are randomized to 1 of 3 arms. ARM 1: Patients receive ruxolitinib o...
News 8 results
https://www.onclive.com/view/itolizumab-under-further-investigation-in-equator-trial-as-frontline-agvhd-treatment
Apr 1st, 2022 - The addition of itolizumab to standard-of-care (SOC) corticosteroids vs placebo will be evaluated in patients with acute graft-versus-host disease (aGVHD), as part of the phase 3 EQUATOR trial (NCT05263999), according to John Koreth, MBBS, DPhil, ...
https://www.mdedge.com/hematology-oncology/article/249256/aml/aml-similar-posttransplant-short-term-outcomes-after
Dec 1st, 2021 - Key clinical point: In patients with acute myeloid leukemia (AML), short-term posttransplant outcomes seemed similar in those who achieved first complete remission (CR1) with either first-line therapy with 5-azacitidine combined with venetoclax (a.
https://www.onclive.com/view/prophylactic-strategies-in-graft-vs-host-disease-management
Nov 15th, 2021 - Transcript: Corey Cutler, MD, MPH, FRCPC: GVHD [graft versus host disease] prophylaxis is universal. The only time that we don’t do prophylaxis is when you have a transplant from identical twins, or when you are using the patient as their own don...
https://www.onclive.com/view/t-cell-depleted-allografts-lessen-gvhd-in-mds
Dec 20th, 2020 - Roni Tamari, MD Treatment with T-cell depleted transplantation was associated with a lower incidence of acute graft versus host disease (GVHD) and a very low incidence of chronic GVHD compared with unmodified allografts in patients with advanced ...
https://www.onclive.com/view/genomic-era-reaches-pediatric-oncology
Dec 5th, 2020 - Rajen Mody, MBBS The relative rarity of pediatric cancers has hampered the work of uncovering their causes and developing new therapies, but efforts to expand the use of genomic and biomarker testing are beginning to provide new options for child...